PMN ProMIS Neurosciences, Inc.

TSX
$14.86

ProMIS Neurosciences, Inc. (PMN) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $1.60 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.8% since its last earnings release on August 13, 2026.

ProMIS Neurosciences Beat Consensus Estimates
Thursday, August 13, 2026 · 4:00 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · After Close
Earnings Whisper
-
vs ($1.60)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $14.86

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330, PMN110, PMN120 and PMN130 which are in its pre-clinical stage. ProMIS Neurosciences Inc.is headquartered in Toronto, Canada.

Sector

Healthcare

Industry

Biotechnology